Literature DB >> 24426236

Correlation and multiple regression analyses of pituitary growth hormone and hepatic activities in hepatitis C infection and interferon response.

Emad F Eskander1, Ahmed A Abd-Rabou2, Shaymaa M M Yahya1, Ashraf El Sherbini3, Mervat S Mohamed4, Olfat G Shaker5.   

Abstract

The prevalence of hepatitis C virus (HCV) infection varies across the world, with the highest percent of infections reported in Middle East, increasingly in Egypt. The current study aimed at examining the bio-statistical correlation and multiple regression analyses of pituitary growth hormone (GH) and liver activities among HCV genotype-4 patients treated with PEG-IFN-α plus RBV therapy. Herein, the current study was conducted on 100 HCV genotype-4 infected patients and 50 healthy controls. Patients received PEG-IFN-α/RBV for 24 weeks. Host RNA was isolated from patients' sera for HCV genotyping and viral load determination. Moreover, the enzymatic activities of the liver, AFP, GH, PT, and CBC were performed in all volunteers. The present study resulted that the activities of the hepatic enzymes among HCV genotype-4 patients correlated together significantly. While, human GH showed a significant positive regression with pre-treatment ALT concentration in responders. Furthermore, multiple regression analysis for GH showed a significant positive correlation with pre-treatment ALT in HCV genotype-4 infected patients. We concluded that there were a putative significant relation between GH and pre-treatment ALT activity in HCV infection and response to IFN-based therapy.

Entities:  

Keywords:  Hepatitis C; Interferon; Liver enzymes; Pituitary growth hormone

Year:  2013        PMID: 24426236      PMCID: PMC3783911          DOI: 10.1007/s12291-013-0309-0

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  39 in total

1.  Potential impact of curcumin and taurine on human hepatoma cells using Huh-7 cell line.

Authors:  Ahmed A Abd-Rabou; Khairy M A Zoheir; Hanaa H Ahmed
Journal:  Clin Biochem       Date:  2012-07-06       Impact factor: 3.281

2.  Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.

Authors:  Xiaowen Su; Leland J Yee; KyungAh Im; Shannon L Rhodes; YongMing Tang; Xiaomei Tong; Charles Howell; Darmendra Ramcharran; Hugo R Rosen; Milton W Taylor; T Jake Liang; Huiying Yang
Journal:  J Hepatol       Date:  2008-05-20       Impact factor: 25.083

Review 3.  Growth hormone. A paracrine growth factor?

Authors:  S Harvey; K L Hull
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

4.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients.

Authors:  Olfat G Shaker; Emad F Eskander; Shaymaa M M Yahya; Mervat S Mohamed; Ahmed A Abd-Rabou
Journal:  Clin Chim Acta       Date:  2010-12-13       Impact factor: 3.786

6.  Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

Authors:  C Niederau; S Lange; T Heintges; A Erhardt; M Buschkamp; D Hürter; M Nawrocki; L Kruska; F Hensel; W Petry; D Häussinger
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

7.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

Review 8.  Treatment predictors of a sustained virologic response in hepatitis B and C.

Authors:  Annika Kau; Johannes Vermehren; Christoph Sarrazin
Journal:  J Hepatol       Date:  2008-07-31       Impact factor: 25.083

9.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.